Clinical Trial Update: A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating oral HP518 in metastatic castration-resistant prostate cancer to assess safety, pharmacokinetics, and anti-tumor activity;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• HP518 (HP518)

Snippet

Sponsor: Hinova Pharmaceuticals Inc. | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1, Phase 2 | Status: RECRUITING